Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 9, Issue 1, Pages 143-150Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.9.1.143
Keywords
antiangiogenesis; clinical trials; hepatocellular carcinoma; multitargeted receptor tyrosine kinase inhibitor; receptor tyrosine kinase; sunitinib; SUTENT (R)
Categories
Funding
- Pfizer
- GlaxoSmithKline
- Bayer
- Amgen
Ask authors/readers for more resources
Sunitinib malate is an oral, multitargeted receptor tyrosine kinase inhibitor of VEGF receptors 1, 2 and 3; PDGF receptors alpha and beta, and other receptor tyrosine kinases implicated in tumor growth, angiogenesis and metastasis. Hepatocellular carcinoma (HCC) is a highly vascular tumor that overexpresses several angiogenic factors; VEGF and PDGF signaling pathways play a key role in HCC. Until recently, treatment options for advanced HCC were limited and conventional therapies have met with poor response rates. Sorafenib provided proof-of-concept for molecularly targeted therapy in advanced HCC and has recently been approved for treatment. However, not all patients can tolerate sorafenib and patients may experience tumor progression; therefore, additional treatment options are warranted. Sunitinib has shown early evidence of anti-tumor activity in Phase II trials in US, European and Asian patients with locally advanced, unresectable and metastatic HCC. A Phase III trial of sunitinib in HCC is ongoing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available